141 related articles for article (PubMed ID: 19306511)
1. Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
Yamamoto Y; Kameyama R; Togami T; Kimura N; Ishikawa S; Yamamoto Y; Nishiyama Y
Nucl Med Commun; 2009 Jan; 30(1):25-9. PubMed ID: 19306511
[TBL] [Abstract][Full Text] [Related]
2. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
3. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour.
Nishiyama Y; Yamamoto Y; Monden T; Sasakawa Y; Tsutsui K; Wakabayashi H; Ohkawa M
Nucl Med Commun; 2005 Oct; 26(10):895-901. PubMed ID: 16160649
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
7. Comparison of early and delayed FDG PET for evaluation of biliary stricture.
Nishiyama Y; Yamamoto Y; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Ohkawa M
Nucl Med Commun; 2007 Dec; 28(12):914-9. PubMed ID: 18090217
[TBL] [Abstract][Full Text] [Related]
8. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
[TBL] [Abstract][Full Text] [Related]
9. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
10. What is the best way to diagnose and stage malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
[TBL] [Abstract][Full Text] [Related]
11. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
12. Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer.
Hu Q; Wang W; Zhong X; Yuan S; Fu Z; Guo H; Yu J
Eur J Radiol; 2009 May; 70(2):320-4. PubMed ID: 18602239
[TBL] [Abstract][Full Text] [Related]
13. The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion.
Sun Y; Yu H; Ma J; Lu P
PLoS One; 2016; 11(8):e0161764. PubMed ID: 27560933
[TBL] [Abstract][Full Text] [Related]
14. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
Basu S; Saboury B; Torigian DA; Alavi A
Mol Imaging Biol; 2011 Oct; 13(5):801-11. PubMed ID: 21136185
[TBL] [Abstract][Full Text] [Related]
15. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
Gerbaudo VH; Mamede M; Trotman-Dickenson B; Hatabu H; Sugarbaker DJ
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):810-21. PubMed ID: 21210110
[TBL] [Abstract][Full Text] [Related]
16. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
[TBL] [Abstract][Full Text] [Related]
17. Dual-phase 18F-FDG PET/CT imaging in the characterization of pancreatic lesions: does it offer prognostic information?
Santhosh S; Mittal BR; Bhasin D; Rana SS; Bhattacharya A; Srinivasan R; Nada R; Gupta R
Nucl Med Commun; 2014 Oct; 35(10):1018-25. PubMed ID: 25023999
[TBL] [Abstract][Full Text] [Related]
18. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
Kaira K; Serizawa M; Koh Y; Takahashi T; Hanaoka H; Oriuchi N; Endo M; Kondo H; Nakajima T; Yamamoto N
Eur J Cancer; 2012 May; 48(8):1244-54. PubMed ID: 22330319
[TBL] [Abstract][Full Text] [Related]
19. Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
Nanni C; Castellucci P; Farsad M; Pinto C; Moretti A; Pettinato C; Marengo M; Boschi S; Franchi R; Martoni A; Monetti N; Fanti S
Cancer Biother Radiopharm; 2004 Apr; 19(2):149-54. PubMed ID: 15186594
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.
Domènech-Vilardell A; Rasiej MJ; Taub RN; Ichise M
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):54-61. PubMed ID: 24727854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
